VANCOUVER, May 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,
Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and
medical device company, today announced the appointment of Dr. Hank
McKinnell to its Board of Directors.
Dr. McKinnell is the former Chief Executive Officer and former Chairman
of the Board of Directors of Pfizer Inc. He is currently Chairman of the
Accordia Global Health Foundation, an organization dedicated to fighting
infectious diseases in Africa, and the Lead Director of the Board of
Directors of Moody's Corporation.
"We are honoured that Dr. McKinnell has agreed to join our Board of
Directors," said Dr. William Hunter, President and CEO of Angiotech. "With
his history and experience in many roles at Pfizer, including as Chairman
and CEO, Dr. McKinnell brings the deep industry knowledge and extraordinary
leadership qualities that we will need to facilitate our continued
evolution into a significant, multinational, operating business in the life
sciences sector."
Dr. McKinnell joined Pfizer in 1971 in Tokyo and over the years, held
positions of increasing responsibility around the world, including service
as President of Pfizer Asia. In 1984, Dr. McKinnell relocated to New York,
where he served as Vice President-Strategic Planning, Chief Financial
Officer, President-Pfizer Medical Device Group, President-Pfizer
Pharmaceuticals Group, and President and Chief Operating Officer. He was
named Chairman and Chief Executive officer in 2001 and served in this role
until his retirement in the second half of 2006.
Dr. McKinnell is the Chairman Emeritus of the Business Roundtable, an
association of the CEOs of America's largest companies, the Pharmaceutical
Research Manufacturers Association, the Food and Drug Law Institute, and
the Medical Device Manufacturers Association. He has also served as vice
chairman of the World Economic Forum, as a member of the WEF Foundation
Board of Trustees, and on the President's Advisory Council on HIV/AIDS.
Dr. McKinnell holds a Bachelor's Degree in business from the University
of British Columbia, and M.B.A. and Ph.D. degrees from the Stanford
University Graduate School of Business.
About Angiotech
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech (NASDAQ:
ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.
CONTACT: Deirdre Neary, Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056,
dneary@angio.com
SOURCE Angiotech Pharmaceuticals, Inc.
 back to top
CONTACT:
Deirdre Neary, Manager, Investor Relations
and Corporate Communications, Angiotech Pharmaceuticals, Inc.,
(604) 222-7056, dneary@angio.com
|
